RASRx is a start-up company dedicated to developing therapies for rare diseases. RASRx will develop and commercialize technology licensed from the University of Southern California.
Research focus: Anti-inflammatory.
“We are passionate about making an impact in healthcare in areas of unmet needs like Duchenne muscular dystrophy. Our lead program at RASRx, which has previously received DoD funding, takes a mutation independent approach to slowing and potentially reversing disease progression to bring relief to patients with Duchenne, and possibly other muscular dystrophies. We are thrilled by the potential of this relationship as CureDuchenne’s knowledge of the disease and familiarity with the needs of the patients are invaluable as we move forward in the development of this promising treatment.” — Kathleen Rodgers, a founder of RASRx